This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Budesonide granules for induction of remission in lymphocytic colitis – first line

< Back

Budesonide granules for induction of remission in lymphocytic colitis – first line


Gastrointestinal, Pancreatic and Liver Disease

September 2020

Budesonide 9mg gastro-resistant granules are in clinical development for the induction of remission in patients with lymphocytic colitis. Lymphocytic colitis is an inflammatory bowel disease that causes bouts of severe diarrhoea. Certain medications, viruses and bacteria can trigger lymphocytic colitis, however the cause of the disease is not known; it is thought that genetic and environmental factors may be involved.

Budesonide is a corticosteroid that exerts anti-inflammatory effects in the gastrointestinal tract. The treatment works by binding with high affinity to intracellular glucocorticoid receptors. In one phase III clinical trial, budesonide was shown to be significantly effective in inducing clinical remission in lymphocytic colitis patients in comparison to a placebo. If licensed, budesonide will offer a treatment option for patients with lymphocytic colitis.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts